Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416125 | 0.92 | MAOB (0.77) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL6005094 | 0.90 | MAOB (0.61) | MAOBNPC1LMNAALDH1A1NR4A2 | |
| SCHEMBL6163210 | 0.89 | MAOB (0.76) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL399151 | 0.87 | MAOB (0.63) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL4510662 | 0.85 | LMNA (0.65) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL10341234 | 0.84 | KDM4E (0.72) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL24254462 | 0.82 | LMNA (0.71) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL30542058 | 0.82 | LMNA (0.71) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL397059 | 0.82 | MAP3K5 (0.57) | MAOBRAB9ANPC1LMNAS1PR1 | |
| SCHEMBL10387779 | 0.82 | NR4A2 (0.55) | MAOBRAB9ANPC1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502914-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | claimed |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | claimed |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2022098879-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL BIOTHERAPEUTICS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| CN-101006076-B | Modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2010-09-29 | — | — | CN | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| CN-101006076-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-07-25 | — | — | CN | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MAOB 2865/4885RAB9A 2557/4885NPC1 28/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | MAOB 2865/4885RAB9A 2557/4885NPC1 28/4885 |
| US-11505528-B2 | Inhibitors of microbially induced amyloid | SNCA, PARK7, PRNP | MAOB 553/4885RAB9A 738/4885NPC1 1829/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MAOB 2865/4885RAB9A 2557/4885NPC1 28/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | MAOB 2865/4885RAB9A 2557/4885NPC1 28/4885 |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | MAOB 852/4885RAB9A 703/4885NPC1 909/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MAOB 2865/4885RAB9A 2557/4885NPC1 28/4885 |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | MAOB 852/4885RAB9A 703/4885NPC1 909/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | MAOB 3796/4885RAB9A 1885/4885NPC1 38/4885 |
| US-20200290970-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | MAOB 553/4885RAB9A 738/4885NPC1 1829/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | MAOB 3602/4885RAB9A 2039/4885NPC1 95/4885 |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | MAOB 3286/4885RAB9A 2101/4885NPC1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.